Clinical trial · Interventional
Extension Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 Trials
An Open Label Extension Trial of Ublituximab and/or Umbralisib (TGR-1202) in Combination With Other Novel Agents or as Single Agents in Subjects Currently Receiving Treatment on a TG Therapeutics Study.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Strategic/Business Decision
Summary
Brief summary (as posted)
This is an open label compassionate use trial of Ublituximab and TGR-1202 in combination or as single agents in patients currently receiving treatment on Ublituximab and/or TGR-1202 trials with B-cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Chronic Lymphocytic Leukemia | Chronic Lymphocytic Leukemia | ONTOLOGY_EXACT | 0.98 |
| Non Hodgkin Lymphoma | Non-Hodgkin Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| TGR-1202 | Drug | — | UNRESOLVED |
| TGR-1202 + Ublituximab | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- TGR-1202
- description
- Oral TGR-1202 Daily
- interventionNames
- Drug: TGR-1202
- type
- EXPERIMENTAL
- label
- TGR-1202 + Ublituximab
- description
- Oral TGR-1202 in combination with Ublituximab intravenous administration
- interventionNames
- Drug: TGR-1202 + Ublituximab
Primary outcomes (1)
- measure
- Adverse Events of TGR-1202 and/or TGR-1202 + ublituximab treatment, including delayed toxicities
- timeFrame
- Evaluated at each planned visit through study completion, an average of 2 years
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Subjects must be currently receiving treatment with ublituximab and/or TGR-1202 on a previously approved protocol. * Subjects must have completed at least 6 cycles of therapy on their current protocol. Exclusion Criteria: * Subject progressed while receiving therapy with ublituximab and/or TGR-1202 while participating in their immediate previous trial.
References
Publications (0)
Data not yet available